Warnings and Precautions Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...
Patients may be eligible for immediate co-pay savings on their next prescription of Sandostatin® LAR Depot (octreotide acetate) for injectable suspension.
* Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit www.Copay.NovartisOncology.com or call 1-877-577-7756.
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting www.Copay.NovartisOncology.com or calling 1-877-577-7756.
Patient Assistance Now Oncology (PANO) is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient Support programs. Dedicated support specialists help direct callers to the services that best fit their needs.
Support for patients includes:
To learn more, call 1-800-282-7630 or visit www.HCP.Novartis.com/Access/.
Q: When can I call the PANO Hotline (1-800-282-7630)?
A: Monday through Friday, 9 AM to 8 PM ET
Q: Do private medical insurance plans and Medicare cover Sandostatin® LAR Depot (octreotide acetate) for injectable suspension?
A: Yes, most do. To learn more, call the PANO Hotline (1-800-282-7630).
Q: Do private medical insurance plans cover Sandostatin® (octreotide acetate) Immediate-Release Injection?
A: Yes, most do. For more information, call the PANO Hotline (1-800-282-7630).
Q: What can I do if a claim is denied?
A: There are several things you can do. First, you can review the patient's EOB form and document the medical necessity for the patient. For more information, call the PANO Hotline (1-800-282-7630).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Please see full Prescribing Information.
Indications and Usage
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.